

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE PCT NATIONAL STAGE APPLICATION OF
FOSTER ET AL.

INTERNATIONAL APPLICATION NO: PCT/EP2003/010579

FILED: 23 SEPTEMBER 2003

U.S. APPLICATION NO: Not Yet Known

35 USC §371 DATE: Herewith

FOR: SPHINGOSINE-1-PHOSPHATE RECEPTOR AGONISTS IN THE
TREATMENT OF DEMYELINATING DISORDERS

MS: Amendment

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

This paper is being filed within three months of the date of entry of the national stage as set forth in 37 C.F.R. §1.491 of the international application. Therefore, no fees are required. If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-0134.

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

The listed references were cited in the international stage search report. Since these references are of record in the instant PCT application PCT/EP2003/010579, copies are not enclosed herewith.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,

Novartis
Corporate Intellectual Property
One Health Plaza, Building 104
East Hanover, NJ 07936-1080
(862) 778-7909

Date: *March 21, 2005*

Thomas R. Savitsky

Thomas R. Savitsky
Attorney for Applicants
Reg. No. 31,661

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

10/528688
Sheet 1 of 1ATTY. FOSTER ET AL.
NOT YET KNOWN
APPLICATION NO. 10/528688
PCT/PTC
FILING DATE
Herewith

21 MAR 2005

Group

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	AM	197 39 693	3/11/99	DE			<input type="checkbox"/>	<input type="checkbox"/>
	AN	1 002 792	5/24/00	EP			<input type="checkbox"/>	<input type="checkbox"/>
	AO	02/072019	9/19/02	WO			<input type="checkbox"/>	<input type="checkbox"/>
	AP	02/18395	3/7/02	WO			<input type="checkbox"/>	<input type="checkbox"/>
	AQ						<input type="checkbox"/>	<input type="checkbox"/>

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

	AR	Brinkman et al., "The Immune Modulator FTY720 Targets Sphingosine 1-Phosphate Receptors", J. Biolog. Chem., Vol. 277, No. 24, pp. 21453-21457 (2002).
	AS	Brinkman et al., "FTY720: Targeting G-Protein-Coupled Receptors for Sphingosine 1-Phosphate in Transplantation and Autoimmunity", Current Opinion in Immunology, Vol. 14, No. 5, pp. 569-575 (2002).
	AT	Hoshino et al., "FTY720, a Novel Immunosuppressant, Shows a Synergistic Effect in Combination with FK 506 in Rat Allograft Models", Transplantation Proceedings, Vol. 31, No. 1-2, pp. 1224-1226 (1999).
	AU	Moser, "Clinical and Therapeutic Aspects of Adrenoleukodystrophy and Adrenomyeloneuropathy", J. Neuropathology and Experimental Neurology, Vol. 54, No. 5, pp. 740-745 (1995).

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.